Scholar Rock filed this application with two fill-finish facilities rather than one, in alignment with FDA guidance, for the stated purpose of creating two independent paths to approval. On Friday one of those paths closed. The FDA classified the April inspection of Catalent Indiana as Official Action Indicated, the most serious of the three available outcomes. The site comes out of the BLA, the second one carries the file, and the 30 September date does not move. Had Catalent been the only fill-finish site named in March, this would be a Complete Response Letter and a delay counted in quarters rather than a release about progress.

• Redundancy in manufacturing is the cheapest insurance in regulatory affairs, and almost nobody buys it. A second fill-finish site means a second validation campaign, a second comparability package and a second inspection exposure, so most sponsors name one facility and save the months. That arithmetic holds right until a classification letter arrives, at which point a sole-source filer has no move available at all. Scholar Rock had one and executed it the same day it was notified. Anyone finalising a BLA that leans on third-party fill-finish should be pricing the second site against the cost of a complete response, not against the cost of validation.
• Competitive frame: the facility that failed belongs to Novo Nordisk, and that is the part worth sitting with. Ownership and scale do not insulate a site from an Official Action Indicated finding, and the consequence lands on the sponsor rather than on the contract manufacturer. Third-party fill-finish is a shared dependency across the industry, so one classification at a large site can stall several unrelated applications at once, filed by companies with no connection to each other. Inspection classifications are a leading indicator on competitors’ timelines and among the least-read datasets available to a CI desk.
• What to watch: Europe, where identical facts have not yet produced an identical result. Scholar Rock is still engaging the EMA on adding the second facility to the MAA and will publish CHMP timelines only once aligned, so the US and EU dates can now diverge on the same underlying fix. Then watch launch readiness rather than the approval itself. Vials already sit at a third-party provider awaiting packaging and labelling, which is a materially stronger position than several approvals covered this month that landed with their launches still months away.